Spiro Kevin Sakiris - 22 Dec 2022 Form 4 Insider Report for INTELLIGENT BIO SOLUTIONS INC. (INBS)

Role
Chief Financial Officer
Signature
/s/ Spiro Sakiris
Issuer symbol
INBS
Transactions as of
22 Dec 2022
Net transactions value
+$19,992
Form type
4
Filing time
23 Dec 2022, 05:06:03 UTC
Previous filing
12 Oct 2022
Next filing
11 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding INBS Common Stock - Prior Balance 125,228 22 Dec 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INBS Series D Convertible Preferred Stock Purchase $13,913 +15,992 +1599200% $0.8700 15,993 22 Dec 2022 Common Stock 15,993 Held by Anest Holdings F1, F2, F3
transaction INBS Common Stock Purchase Warrant Purchase $6,079 +47,979 $0.1267* 47,979 22 Dec 2022 Common Stock 47,979 $0.2900 Held by Anest Holdings F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Series D Convertible Preferred Stock is initially convertible into three shares of common stock of the Issuer. The conversion ratio is subject to adjustment. Following the Trigger Date (defined below), each share of Series D Convertible Preferred Stock is convertible at any time at the option of the holder and without payment of further consideration. The Series D Convertible Preferred Stock has no expiration date. As used herein, "Trigger Date" means the earlier to occur of (i) the date that the last of (a) the Issuer's shareholders approve the conversion of the Series D Convertible Preferred Stock or (b) the Issuer's shareholders approve a reverse split of the Issuers's common stock, or (ii) the date which is 60 days following the date on which the Common Stock is no longer listed on the Nasdaq Stock Market, the New York Stock Exchange or the NYSE American.
F2 On December 22, 2022, Anest Holdings Pty Ltd, as trustee of ATF S&T Sakiris Superannuation Fund, purchased 15,993 units from the Issuer in a private placement. Each unit consists of one share of Series D Convertible Preferred Stock (valued at $0.87 each) and three common stock purchase warrants (collectively valued at $0.35, or $0.1267 each). The purchase price of each unit was $1.25 per unit.
F3 These securities are held by Anest Holdings Pty Ltd, as trustee of ATF S&T Sakiris Superannuation Fund, of which Mr. Sakiris is a Director.
F4 Subject to adjustment.